Microbot Medical Inc (MBOT) Actualités

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form PRE 14A - Other preliminary proxy statements

Form D - Notice of Exempt Offering of Securities

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Microbot Medical Closes $13 Million Registered Direct Offering

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]